RT Journal Article
SR Electronic
T1 Joint-Label Fusion Brain Atlases for Dementia Research in Down Syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.10.20228742
DO 10.1101/2020.11.10.20228742
A1 Queder, Nazek
A1 Phelan, Michael J.
A1 Taylor, Lisa
A1 Tustison, Nicholas
A1 Doran, Eric
A1 Hom, Christy
A1 Nguyen, Dana
A1 Lai, Florence
A1 Pulsifer, Margaret
A1 Price, Julie
A1 Kreisl, William C.
A1 Rosas, Diana H.
A1 Krinsky-McHale, Sharon
A1 Brickman, Adam
A1 Yassa, Michael A.
A1 Schupf, Nicole
A1 Silverman, Wayne
A1 Lott, Ira T.
A1 Keator, David B.
YR 2020
UL http://medrxiv.org/content/early/2020/11/13/2020.11.10.20228742.abstract
AB Research suggests a link between Alzheimer’s Disease in Down Syndrome (DS) and the overexpression of amyloid plaques. Using Positron Emission Tomography (PET) we can assess the in-vivo regional amyloid load using several available ligands. To measure amyloid distributions in specific brain regions, a brain atlas is used. A popular method of creating a brain atlas is to segment a participant’s structural Magnetic Resonance Imaging (MRI) scan. Acquiring an MRI is often challenging in intellectually-imparied populations because of contraindications or data exclusion due to significant motion artifacts or incomplete sequences related to general discomfort. When an MRI cannot be acquired, it is typically replaced with a standardized brain atlas derived from neurotypical populations which may be inappropriate for use in DS. In this project, we create a series of disease and diagnosis-specific (cognitively stable, mild cognitive impairment (MCI-DS), and dementia) probabilistic group atlases of participants with DS and evaluate their accuracy of quantifying regional amyloid load compared to our ground truth individual MRI-based segmentations. Further, we compare the diagnostic-specific atlases with a probabilistic atlas constructed from similar-aged cognitively-stable neurotypical participants. We hypothesized that regional PET signals will best match the ground truth by using DS group atlases that aligns with a participant’s disorder and disease status (e.g. DS and MCI-DS). Our results vary by brain region but generally show that using a disorder-specific atlas in DS better matches the ground truth than using an atlas constructed from cognitively-stable neurotypical participants. We found no additional benefit of using a disease-state specific atlas. All atlases are made publicly available for the research community.Abbreviations AD, DS, Aβ, DSG, CS-DS, CS-NT, LOOCV, ROI, MSE, MRI, PET, JLF, CS, MCI-DS, DEM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe preparation of this manuscript was made possible from data obtained by the Alzheimers Disease in Down Syndrome (ADDS) component of the Alzheimers Biomarkers Consortium Down Syndrome (ABC DS), a longitudinal study of Alzheimer Disease biomarkers in adults with Down syndrome is supported by grants from the National Institute on Aging (NIA) (U01AG051412 01 Schupf, Lott, Silverman) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The Co-Principal Investigators of the ADDS component of the ABC-DS program are Nicole Schupf, PhD, Dr PH. (Columbia University), Ira Lott, MD and Wayne Silverman, Ph.D. (UC Irvine). Co-Principal Investigators of the NiAD ABC-DS component are Benjamin Handen, PhD and William Klunk, MD, PhD, (University of Pittsburgh), and Bradley Christian, PhD (University of Wisconsin Madison) Neurotypical data was collected under the Neuroimaging biomarkers for cognitive decline in elderly with amyloid pathology (NIA) grant from the National Institute of Aging (R01AG053555 Yassa, Gillen). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Protocols for this study were reviewed and approved by the local Institutional Review Boards at participating institutions (University of California, Irvine, Massachusetts General Hospital and New York State Institute for Basic Research in Developmental Disabilities, Columbia University Irving Medical Center). Informed consent was obtained either from participants or their legally authorized representatives along with participant assent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe down Syndrome datasets used for this study is made available by the ABC-DS consortium (Crawford, n.d.)